{
  "id": 15587238,
  "title": "Mabwell presents Phase II trial results for breast cancer drug 9MW2821",
  "url": "https://urgent.news/2026/10/19/mabwell-presents-phase-ii-trial-results-for-breast-cancer-drug-9mw2821",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T09:13:43.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/mabwell-presents-phase-ii-trial-results-for-breast-cancer-drug-9mw2821-163169.html"
  },
  "original_language": "en",
  "account": "SHANGHAI, Oct. 19, 2026 - Mabwell, a biopharmaceutical company based in Shanghai, will showcase Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 during the 2026 European Society for Medical Oncology (ESMO) Congress. The study examines the potential of 9MW2821 in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received an ADC containing topoisomerase I inhibitor payload.",
  "summary": "Biopharmaceutical firm Mabwell scheduled Phase II clinical trial data presentations for its Nectin 4 targeting antibody drug conjugate 9MW2821 at the European Society for Medical Oncology Congress",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Disc Medicine reports 'sun allergy' drug hits Phase 3 home run",
        "url": "https://urgent.news/2026/10/19/disc-medicine-reports-sun-allergy-drug-hits-phase-3-home-run",
        "published": "2026-10-19T11:00:36.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}